The optimal window of time to stimulate heart muscle cell regeneration — cardiomyocyte proliferation — in humans is the first six months of life, researchers have discovered. The drug neuregulin is currently under investigation as a drug treatment for heart failure in adults, but corresponding studies for pediatric applications had not been attempted before now.